New treatment for severe respiratory distress syndrome
Official title: Novel therapeutic approach for severe ARDS with a potent pharmacologic allosteric hemoglobin modifier
Funded at Illexcor Therapeutics, LLC · NIH-10875488 · Data updated 2026-11-12
This study is testing a new medication that could help people with severe breathing problems caused by ARDS by improving how well their bodies deliver oxygen, and it's designed for patients who are struggling with this serious condition.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Illexcor Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Richmond, United States) |
| Project start | January 1, 2021 |
| Project end | June 30, 2026 |
| Funding year | 2024 |
| Award (this year) | $807,795 |
| NIH project number | 5R44HL156334-03 |
| Project ID | NIH-10875488 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include adults diagnosed with severe acute respiratory distress syndrome who are experiencing significant respiratory failure.
✕Less likely to help
Patients with mild respiratory issues or those not diagnosed with ARDS may not benefit from this research.
What this research studies
This research investigates a novel pharmacologic approach to treat severe acute respiratory distress syndrome (ARDS), a critical condition characterized by severe breathing difficulties and low oxygen levels. The study aims to develop a potent allosteric hemoglobin modifier that could enhance oxygen delivery to tissues, potentially improving patient outcomes. By focusing on a new therapeutic strategy, the research seeks to address the limitations of current treatments, which often fail to significantly reduce mortality rates in ARDS patients. The methodology involves clinical trials to evaluate the safety and efficacy of this new treatment in affected individuals.
Why it matters
Potential benefit: If successful, this research could significantly improve survival rates and quality of life for patients suffering from severe ARDS.
How similar studies have gone: While there have been advancements in ARDS treatment, this approach is novel and has not been extensively tested in clinical settings.
Where this research is happening
-
Illexcor Therapeutics, LLC
Richmond, United States Active
Researchers
- Principal investigator: Light, David Richard — Illexcor Therapeutics, LLC
- Study coordinator: Light, David Richard
Related research
Other NIH-funded projects on the same topics.
-
Coordinating ARDS, Pneumonia, and Sepsis research to improve care
A national coordinating center helps researchers studying ARDS and related infections work together more efficiently to learn what helps patients recover.
-
Lipid-gene Profiles in Septic ARDS
A Mayo Clinic team is studying how dysfunctional HDL in sepsis relates to different ARDS patient outcomes, aiming to find features that could guide better treatment.
-
Improving blood vessel repair after pediatric ARDS
Aims to better repair the lungs of children who have ARDS by delivering targeted therapy to lung blood vessels using tiny nanoparticles.
-
NOX4 links to ARDS risk and progression
Aims to understand how NOX4-driven cell damage may make some adults with ARDS worse off and how this could lead to earlier, targeted care.
-
Leading causes of death in alcoholic ARDS patients using clinical data
This project uses big clinical data and AI to find the main factors that cause death in adults with ARDS who have alcohol use issues, aiming to improve understanding and care.
-
Targeting aging-related blood vessel injury to prevent ARDS in older lungs
Aims to find ways to protect lung blood vessels in older adults to prevent dangerous lung swelling (ARDS).
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.